(1999) also collected data on sulfides
E., Xu, W., Hamilton, A., Huss, J
Symptom changes, like less postworkout soreness or better recovery from alcohol, can appear sooner but are subjective
KPV NF-kB suppression would affect inflammation regardless of location
ISBN 978-0813826301
Disclosures: Lesley Patmore: Gilead Sciences: Consultant, Lilian Yan Liang: Nothing to Disclose, Mai Kilany: Nothing to Disclose, Arno Furqium d'Almeida: Nothing to Disclose, Vincent Wong: Nothing to Disclose, Thomas Vanwolleghem: Johnson and Johnson: Advisor, GSK: Grant/Research Support, Fujirebio: Grant/Research Support, Gilead Sciences: Speaking and Teaching, Abbvie: Speaking and Teaching, Pieter Honkoop: Nothing to Disclose, Hans Blokzijl: Nothing to Disclose, zgr Muhammet Koc: Nothing to Disclose, Harry Janssen: Gilead Sciences: and consultant, Gilead Sciences: Grant/Research Support, GlaxoSmithKline: Grant/Research Support, Janssen: Grant/Research Support, Roche: Grant/Research Support, Vir Biotechnology Inc.: Grant/Research Support, Aligos: Consultant, Gilead Sciences: Consultant, GlaxoSmithKline: Consultant, Grifols: Consultant, Roche: Consultant, Vir Biotechnology Inc: Consultant, Precision Biosciences: Consultant, Matthijs Kramer: Dr Falk: Sponsoring of educational meetings, Joep de Bruijne: Nothing to Disclose, Apichat Kaewdech: Nothing to Disclose, Robert De Man: roche diagnostics: Grant/Research Support, Bart Takkenberg: Nothing to Disclose, Grace Lai-Hung Wong: AstraZeneca, Gilead Sciences, GlaxoSmithKline and Janssen,: Advisor, Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Gi: Speaking and Teaching, Gilead Sciences: Grant/Research Support, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support, Milan Sonneveld: Nothing to Disclose 2650 REPRESENTATION OF GENDER, RACIAL, AND ETHNIC MINORITIES IN HEPATOLOGY CLINICAL TRIALS KIN LI, DO 1 , MUHAMMED BOUSO, MD 1 , MALIK MUSHANNEN, MD 1 , CARLA PELLERGRINO, MD 1 , JOSHUA HARROCH, MD 1 , GRES KARIM, MD 2 , NICHOLAS BROWN, MD 2,3,4 , ILAN WEISBERG, MD 2,3 1 NEW YORK PRESBYTERIAN - BROOKLYN METHODIST, DEPARTMENT OF MEDICINE, BROOKLYN, NY 11215 2 NEW YORK PRESBYTERIAN - BROOKLYN METHODIST, DEPARTMENT OF GASTROENTEROLOGY, BROOKLYN, NY 11215 3 WEILL CORNELL MEDICINE, DEPARTMENT OF GASTROENTEROLOGY, NEW YORK, NY 10021 4 COLUMBIA UNIVERSITY IRVING MEDICAL CENTER, DEPARTMENT OF GASTROENTEROLOGY, NEW YORK, NY 10032 Kin Li 1 Fouad Bouso 1 Malik Mushannen 1 Joshua Harroch 1 Carla Pellegrino 1 Gres Karim 1 Nicholas Brown 1 Ilan Weisberg 2 , 1 New York Presbyterian - Brooklyn Methodist, 2 Weill Cornell Medicine Background: Historically, clinical trials in the United States have overrepresented White male participants, which may lead to significant gaps in our understanding of disease manifestations and treatment responses among different demographic groups
